Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Average Rating of “Buy” by Analysts

Zealand Pharma A/S (OTCMKTS:ZLDPF) has been given an average recommendation of “Buy” by the seven brokerages that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and five have given a strong buy rating to the company.

ZLDPF has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. BTIG Research raised Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF opened at $62.10 on Wednesday. The company’s 50 day simple moving average is $69.40 and its 200-day simple moving average is $70.52. The firm has a market cap of $4.41 billion, a PE ratio of 4.47 and a beta of 0.72. Zealand Pharma A/S has a 12-month low of $49.98 and a 12-month high of $108.30. The company has a current ratio of 14.10, a quick ratio of 14.10 and a debt-to-equity ratio of 0.02.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.